Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Respiratory disease focused Verona Pharma booked a first-half loss, as it ramped up research and development spending.
Pre-tax losses for the six months through June amounted to £17.8m, compared to losses of £16.5m on-year.
R&D costs rose to £15.8m, up from £8.3m on-year.
The company is currently proving up the efficacy of its ensifentrine candidate for the treatment of chronic obstructive pulmonary disease.
At 9:17am: (LON:VRP) Verona Pharma PLC share price was -0.7p at 47.3p